Pharmacogenomics is essential in understanding the implications of APRT deficiency. Genetic screening can identify individuals at risk, allowing personalized medicine approaches to optimize treatment and minimize adverse outcomes. This is particularly important in populations with a higher prevalence of APRT deficiency due to genetic factors.
